LIANY
Lianbio
A biopharmaceutical company that acted as a bridge for Western drugmakers wanting to enter China, in-licensing experimental medicines from partners like Pfizer and BridgeBio and running their clinical trials in Asia across oncology, heart disease, and eye care. Founded in 2019 by the American investment firm Perceptive Advisors, it took its name from the Chinese character "lián," meaning "to link" or "to connect" — a nod to its mission of linking global innovation with the Chinese market. In 2024 it wound down its drug business and later merged into LianMedical, a medical-device company starting with heart-failure treatments.
ADRUnderlying: LIANYCUSIP: 53000N108HealthcareCN1 holder
Sponsored ADR — Delisted from Nasdaq, shut down operations in 2024